Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)
Phase 2
Recruiting
- Conditions
- High Risk Prostate Carcinoma
- Interventions
- Radiation: Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT06461793
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Pilot Study for the Validity of a Content-based Information Provision Tool Aimed at Improving the Hospitalization Experience of Liver Transplant Patients
Not Applicable
Not yet recruiting
- Conditions
- Liver TransplantationInpatients
- Interventions
- Other: Consolidating content on a single website and providing access to it via QR codes in a brochure format
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT06424808
Maternal and Offspring Outcomes in Pregnant Women With Pre-existing ASCVD
Recruiting
- Conditions
- AtherosclerosisPregnancy ComplicationsAdverse Cardiac EventCardiovascular DiseasesAdverse Birth Outcomes
- Interventions
- Other: Pre-existing atherosclerotic cardiovascular disease
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 5461222
- Registration Number
- NCT06406998
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Patritumab Deruxtecan in Patients with Solid Tumor Harboring an NRG1 Fusion
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06383884
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Time From PCI to Cancer Surgery and Cardiovascular and Oncologic Outcomes
Completed
- Conditions
- Coronary Artery DiseaseCancer
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 3621
- Registration Number
- NCT06357000
The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
Phase 4
Not yet recruiting
- Conditions
- Heart Failure, Preserved Ejection Fraction
- Interventions
- Drug: SGLT2 inhibitor
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 154
- Registration Number
- NCT06350487
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients
Not Applicable
Recruiting
- Conditions
- Parkinson's Disease and Parkinsonism
- Interventions
- Device: High-Frequency, bilateral M1Device: High-Frequency, Lt. DLPFCDevice: High-Frequency, ipsilateral M1
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT06350617
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI
Completed
- Conditions
- Coronary Artery DiseaseHyperlipidemias
- Interventions
- Drug: LDL reduction therapy
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 135877
- Registration Number
- NCT06338956
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Switching to E-cigarette After PCI
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Behavioral: Switching to E-cigaretteBehavioral: Smoking cessation
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 17973
- Registration Number
- NCT06338761
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Not Applicable
Recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Diagnostic Test: GeoMx data analysis with clinical outcome
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT06330012
- Locations
- 🇰🇷
Ji-Yeon Kim, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath